AstraZeneca
- Home
- Companies
- AstraZeneca
- Products
- Model AZD2373 Phase I - Nephropathy
Model AZD2373 Phase I - Nephropathy
FromAstraZeneca
Mechanism: Podocyte health; Area under investigation: nephropathy; Date commenced phase: Q1 2020; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule; Status change.